MSCV-BRD9_N216A-PGK-Puro-IRES-GFP Citations (2)

Originally described in: Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
Hohmann AF, Martin LJ, Minder JL, Roe JS, Shi J, Steurer S, Bader G, McConnell D, Pearson M, Gerstberger T, Gottschamel T, Thompson D, Suzuki Y, Koegl M, Vakoc CR Nat Chem Biol. 2016 Jul 4. doi: 10.1038/nchembio.2115. PubMed Journal

---

Articles Citing MSCV-BRD9_N216A-PGK-Puro-IRES-GFP

Articles
BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression. Alpsoy A, Utturkar SM, Carter BC, Dhiman A, Torregrosa-Allen SE, Currie MP, Elzey BD, Dykhuizen EC. Cancer Res. 2021 Feb 15;81(4):820-833. doi: 10.1158/0008-5472.CAN-20-1417. Epub 2020 Dec 21. PubMed
BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state. Xiao M, Kondo S, Nomura M, Kato S, Nishimura K, Zang W, Zhang Y, Akashi T, Viny A, Shigehiro T, Ikawa T, Yamazaki H, Fukumoto M, Tanaka A, Hayashi Y, Koike Y, Aoyama Y, Ito H, Nishikawa H, Kitamura T, Kanai A, Yokoyama A, Fujiwara T, Goyama S, Noguchi H, Lee SC, Toyoda A, Hinohara K, Abdel-Wahab O, Inoue D. Nat Commun. 2023 Dec 15;14(1):8372. doi: 10.1038/s41467-023-44081-6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.